A Pilot Evaluation of the Safety, Tolerability, Pharmacokinetics, and Effectiveness of Memantine in Pediatric Patients with Attention-Deficit/Hyperactivity Disorder Combined Type

Findling, Robert L.; McNamara, Nora; Stansbrey, Robert J.; Maxhimer, Rebecca; Periclou, Antonia; Mann, Allison; Graham, Stephen M.

doi:10.1089/cap.2006.0044

Cited by 67 publications

(38 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…On the basis of the results of an open-label 8-wk trial with memantine in 6-12 years old outpatients with ADHD combined type, it has been suggested the use of memantine in children with ADHD [119] . Memantine was also associated with a statistically significant improvement in the global symptomatology, inattentive and hyperactive symptoms as measured with the Adult ADHD Investigator Symptom Report in a sample of adult ADHD patients.…”

Section: Memantine In Treatment-resistant Bipolar Disorder: Clinical mentioning

confidence: 99%

Memantine: New prospective in bipolar disorder treatment

Serra

Demontis

Serra

et al. 2014

WJP

View full text Add to dashboard Cite

Section: Memantine In Treatment-resistant Bipolar Disorder: Clinical mentioning

confidence: 99%

Memantine: New prospective in bipolar disorder treatment

Serra

Demontis

Serra

et al. 2014

WJP

View full text Add to dashboard Cite

“…Of those, only the following events were reported in more than 1 patient: nervousness (n = 6), convulsions (n = 4), tremor (n = 3), aggressive reaction (n = 3), circulatory failure (n = 2), hypertension (n = 2), dizziness (n = 2), dyskinesia (n = 2), nausea (n = 2), menstrual disorder (n = 2), bullous eruption (n = 2), and pruritus (n = 2). Recent open-label studies suggest that memantine may be clinically useful and well tolerated in young individuals with other conditions that produce cognitive disabilities, such as autism and attention deficit hyperactivity disorder [81][82][83] .…”

Section: Memantine and The First Translational Clinical Trial In Dsmentioning

confidence: 99%

On the Promise of Pharmacotherapies Targeted at Cognitive and Neurodegenerative Components of Down Syndrome

Costa¹

2011

Dev Neurosci

View full text Add to dashboard Cite

Down syndrome (DS) is the phenotypic consequence of trisomy 21 and is the most common genetically defined cause of intellectual disability. The most complete, widely available, and well-studied animal model of DS is the Ts65Dn mouse. Recent preclinical successes in rescuing learning and memory deficits in Ts65Dn mice are legitimate causes for optimism that pharmacotherapies for cognitive deficits in DS might be within reach. This article provides a snapshot of potential pharmacotherapies for DS, with emphasis on our recent results showing that the N-methyl-<i>D</i>-aspartate receptor antagonist memantine can reverse learning and memory deficits in Ts65Dn mice. Because memantine has already been approved for the therapy of Alzheimer’s dementia, we have been able to very rapidly translate these results into human research and are currently conducting a 16-week, randomized, double-blind, placebo-controlled evaluation of the efficacy, tolerability and safety of memantine hydrochloride on enhancing the cognitive abilities of young adults with DS. The design and current status of this clinical trial will be discussed, which will be followed by some speculation on the potential impact of this and future clinical trials in the field of DS.

show abstract

“…Memantine did not differentate from placebo in an 8-week trial of adjunctive therapy in 138 adults with schizophrenia (Lieberman et al 2008). In 16 youth (ages 6-12 years) with ADHD, 20 mg/day of memantine was associated with larger mean improvement in symptoms over 8 weeks of open-label treatment compared to a 10 mg/day dose (Findling et al 2007). In this pilot ADHD study, memantine was well tolerated with no drug discontinuations due to adverse effects.…”

Section: Introductionmentioning

confidence: 71%

Open-Label Memantine in Fragile X Syndrome

Erickson

Mullett

McDougle

2009

J Autism Dev Disord

View full text Add to dashboard Cite

Glutamatergic dysfunction is implicated in the pathophysiology of fragile X syndrome (FXS). The purpose of this pilot study was to examine the effectiveness and tolerability of memantine for a number of target symptoms associated with FXS. Medical records describing open-label treatment with memantine in 6 patients with FXS and a comorbid diagnosis of PDD were reviewed. Six patients received memantine over a mean 34.7 weeks of treatment. Four of 6 (67%) patients showed global clinical benefit on ratings with the CGI-I. Symptom specific rating scales, however, showed no statistically significant improvement. Two patient developed treatment-limiting irritability on memantine. Memantine was modestly effective in several patients with FXS. Further systematic study is warranted.

show abstract

A Pilot Evaluation of the Safety, Tolerability, Pharmacokinetics, and Effectiveness of Memantine in Pediatric Patients with Attention-Deficit/Hyperactivity Disorder Combined Type

Abstract: This pilot study suggests that a memantine dose of 20 mg/day may be a safe and possibly effective treatment for pediatric ADHD. Further investigations of memantine in ADHD appear to be warranted.

Cited by 67 publications

References 19 publications

Memantine: New prospective in bipolar disorder treatment

Memantine: New prospective in bipolar disorder treatment

On the Promise of Pharmacotherapies Targeted at Cognitive and Neurodegenerative Components of Down Syndrome

Open-Label Memantine in Fragile X Syndrome

Contact Info

Product

Resources

About